Ventricular hypertrophy and carotid atherosclerosis
Conditions
Interventions
All patients will receive the same imunossupressive drugs in the beginning of the transplantation: tacrolimo (0,2mg/Kg and frequent readjusts tom maintain a serum level between 20 and 15 ng/ml during
Drug
Other
D02.540.505.810
Sponsors
Hospital das Clínicas da Faculdade de Medicina de Botucatu
Hospital das Clínicas da Faculdade de Medicina de Botucatu
Eligibility
Age
30 Years to No maximum
Inclusion criteria
Inclusion criteria: The patient who agree to participate in the study, who have a consent form signed and meet the following criteria: age of 30 years or greater and being a recipient of de novo kidney transplant from a deceased donor or non-HLA identical living donor. At randomization time the patients needs to meet this criteria: creatinine clearance estimated by Cockroft-Gault formula of 40ml/min or greater and proteinuria of 800mg/day or less.
Exclusion criteria
Exclusion criteria: Patients will be excluded of the study if: with painel reactive antibody of 50% or higher, recipients of a second transplant with the first transplant loss for any immunological cause within the first year of transplantation, multi-organ recipient, ABO incompatible donor; non-beating heart donor; donor age of 5 yars or less and donor age of 65 years or higher. At the randomization time, patients will be excluded if: they were on a rejection treatment, if they have history of Baff IIB or higher rejection insult, previous rejection resistant to corticosteroids, presence of subclinical rejection or severe inflammation on protocolar biopsy, presence of total blood cont leucocyte of 2500uL or less, neutrofiles of 1500uL or less, platelets of 75000uL or less, hemoglobin of 6,0g/L or less, liver disease or active infection, positive pregnancy test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of carotid atheromatous plaque thickness assessed by carotid Doppler ultrasound and reduction of left ventricular mass after 6 months and 1 year of the randomization in renal transplanted patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences relative to creatinine clearance and number of biopsy-proven acute rejection episodes. | — |
Countries
Brazil
Contacts
Public ContactPaula Garcia
Hospital das Clínicas da Faculdade de Medicina de Botucatu
Outcome results
None listed